Mark Hahn - Feb 1, 2025 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Chief Financial Officer
Signature
/s/ Anderw Fisher, Attorney-in-fact for Mark Hahn
Stock symbol
VRNA
Transactions as of
Feb 1, 2025
Transactions value $
-$1,195,335
Form type
4
Date filed
2/4/2025, 04:30 PM
Previous filing
Dec 6, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Award $0 +200K +1.5% $0.00 13.5M Feb 1, 2025 Direct F1, F2
transaction VRNA Ordinary Shares Tax liability -$1.2M -167K -1.24% $7.16 13.3M Feb 3, 2025 Direct F1, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 Represents an award of Ordinary Shares upon vesting of Performance Restricted Share Units in connection with the Issuer's first commercial sale of ensifentrine.
F3 Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units and the Performance Restricted Share Units.
F4 The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on January 31, 2025 divided by eight (8).
F5 Consists of (i) 2,725,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 340,625 ADSs); and (ii) 10,601,848 Ordinary Shares underlying 1,325,231 ADSs.